MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Evaluating the association between cognitive impairment and striatal VMAT2 binding using [18F]AV-133 PET in Parkinson’s disease

K. Hwang, J. Langley (Long Beach, USA)

Meeting: 2024 International Congress

Abstract Number: 1051

Keywords: Cognitive dysfunction, Parkinson’s, Vesicle monamine transporter(VMAT2)

Category: Parkinson's Disease: Neuroimaging

Objective: To evaluate the association between cognitive deficits and striatal vesicular monoamine transporter type 2 (VMAT2) binding in participants with Parkinson’s disease (PD) using [18F]AV-133 tracer positron emission tomography (PET) scans from the Parkinson’s Progression Marker’s Initiative (PPMI)

Background: Cognitive impairment is common in PD and 50-80% of patients develop dementia as PD progresses. Dopaminergic and monoaminergic dysfunction are potential mechanisms for cognitive decline in PD. Presynaptic and synaptic dopamine function can be evaluated using VMAT2 PET imaging and 123I-FP-CIT SPECT imaging (DaTSCAN), respectively. The relationship between cognitive deficits and striatal dopamine dysfunction as measured by VMAT2 PET imaging has not been fully established.

Method: Data was obtained from the PPMI database (www.ppmi-info.org/data). 31 PD participants had MRI, DaTSCAN, and [18F]AV-133 PET (VMAT2) scans at the baseline visit. PET and SPECT scans were registered to each participant’s T1-weighted MRI and partial volume corrected (figure 1). VMAT2 and DaT binding ratios (VBR and DBR) in the caudate and putamen were extracted from the VMAT2 and DaTSCAN images, respectively. Montreal Cognitive Assessment (MoCA), Trail Making Test Parts A & B (TMT A & TMT B), Clock Draw and FAS were used to evaluate frontal-executive cognitive deficits. Partial correlations were used to assess the relationship between cognitive test scores and mean caudate and putamen VBR and DBR while adjusting for age, education, disease duration and Unified Parkinson’s Disease Rating Scale part 3 score (UPDRS-III) with a p-value threshold of 0.05.

Results: Demographic and clinical assessments are shown in table 1. A significant negative correlation between TMT B and mean VBR was seen in the caudate (r=-0.597, p=0.003) but not in the putamen (table 2). Mean caudate/putamen VBR showed significant positive correlations with clock draw (r=0.462, p=0.031) and total FAS score (r=0.455, p=0.033). There were no significant associations between TMT B, clock draw and FAS with DBR. There were no significant correlations between MoCA and TMT A with VBR or DBR.

Conclusion: Striatal dopamine dysfunction in the caudate as measured by [18F]AV-133 PET imaging may be a promising marker associated with executive cognitive dysfunction in early PD.

Figure 1

Figure 1

Table 1

Table 1

Table 2

Table 2

To cite this abstract in AMA style:

K. Hwang, J. Langley. Evaluating the association between cognitive impairment and striatal VMAT2 binding using [18F]AV-133 PET in Parkinson’s disease [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/evaluating-the-association-between-cognitive-impairment-and-striatal-vmat2-binding-using-18fav-133-pet-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluating-the-association-between-cognitive-impairment-and-striatal-vmat2-binding-using-18fav-133-pet-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley